Special Track Session 6
Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences + Oncology & Theranostics Committee

Round Table
Monday, September 11, 09:45 – 11:15

Session Title
Dialogue with the Treating Physician

Moderators
Margret Schottelius (Lausanne, Switzerland)
Ken Herrmann (Essen, Germany)

Round Table Participants
Antonia Digklia (Lausanne, Switzerland) - Immunoocologist
Christel Kamani (Leeds, UK) - Cardiologist
Tobias Maurer (Hamburg, Germany) - Urologist
Emmanuella Guenova-Hoetzenecker (Lausanne, Switzerland) - Dermatologist
Egesta Lopci (Rozzano, Italy) - Nuclear Medicine Physician
Peter Laverman (Nijmegen, The Netherlands) - Radiopharmacist

Educational Objectives
1. Gain insight into the current most urgent clinical needs for appropriate imaging approaches in different clinical disciplines
2. Sharpen awareness for potential divergences between “trends in tracer development” and “clinical need”
3. Broaden perspectives on potential new routes towards strengthened interaction of nuclear medicine/radiopharmaceutical development with clinical disciplines and thus towards creating greater impact of nuclear medicine in patient management

Summary
This session will consist of 4 short talks by clinicians from different disciplines (Immunooncology, Urology, Dermatology, Cardiology). All participants are asked to shortly present the answers to the following three questions:
1. Which imaging modalities are you currently using for disease detection/staging/patient selection/therapy control?
2. What are the biggest, unsolved clinical problems (regarding disease detection/staging/patient selection/therapy control) you are facing?
3. What tools would you – in an ideal world - need from radiopharmaceutical development and nuclear imaging/theranostics to be able to address these problems?
These presentations will be followed by two short presentations by a nuclear medicine physician and a radiopharmacist, providing answers to the following questions:

- What are the most relevant nuclear medicine tools/developments currently available for disease detection/staging/patient selection/therapy control?
- What is, in your opinion, the most relevant clinical need that should be addressed in the next years (by means of tracer/method development)?
- Is the current direction in tracer development aligned with these needs and where should it head within the next 5 years?

Presentations will then be followed by a round table discussion with a focus on aligning the direction of tracer and method development in Nuclear Medicine with the most important clinical needs identified for the different disciplines. It is planned to summarize the presentations and the outcome of the following discussion in a joint Editorial/Position Paper in EJNMMI.

**Key Words**
Radiopharmaceuticals, Imaging, Theranostics, Immunooncology, Urology, Cardiology, Dermatology